Last reviewed · How we verify
pazopanib and pemetrexed
pazopanib and pemetrexed is a Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 2 development.
At a glance
| Generic name | pazopanib and pemetrexed |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer (PHASE1)
- A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors (PHASE1)
- A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population (PHASE2)
- Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pazopanib and pemetrexed CI brief — competitive landscape report
- pazopanib and pemetrexed updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about pazopanib and pemetrexed
What is pazopanib and pemetrexed?
pazopanib and pemetrexed is a Small molecule drug developed by GlaxoSmithKline.
Who makes pazopanib and pemetrexed?
pazopanib and pemetrexed is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is pazopanib and pemetrexed in?
pazopanib and pemetrexed is in Phase 2.
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Compare: pazopanib and pemetrexed vs similar drugs
- Pricing: pazopanib and pemetrexed cost, discount & access